Surgi-One will distribute the product, which is cleared for use in spine and general orthopedic procedures, the orthobiologics company said in a Nov. 5 news release.
I-Factor+ Matrix uses a peptide technology to promote bone growth through cell attraction, attachment and activation.
The FDA is evaluating the product in an investigational device exemption study for lumbar fusions.
I-Factor+ Matrix has not been approved for use in the U.S.
More articles on biologics:
Orthopedic surgery has 3rd highest gender wage gap among medical specialties, report finds
A timeline of Medtronic’s 7 deals so far in 2020
Robots will never replace surgeons, but can prove useful partners: 3 spine surgeons weigh in
